Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
36.11
-0.57 (-1.55%)
Jul 22, 2026, 4:00 PM EDT - Market closed
Neurogene Employees
Neurogene had 131 employees as of December 31, 2025. The number of employees increased by 24 or 22.43% compared to the previous year.
Employees
131
Change (1Y)
24
Growth (1Y)
22.43%
Revenue / Employee
n/a
Profits / Employee
-$752,962
Market Cap
719.56M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 131 | 24 | 22.43% |
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Jun 30, 2023 | 82 | - | - |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Rigel Pharmaceuticals | 174 |
| Aura Biosciences | 113 |
| Aclaris Therapeutics | 73 |
| CytomX Therapeutics | 69 |
| Zevra Therapeutics | 61 |
| Oculis Holding AG | 60 |
| Candel Therapeutics | 55 |
| Design Therapeutics | 54 |
NGNE News
- 16 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 22 days ago - Neurogene prices 3.5M shares at $30.00 in public offering - TheFly
- 22 days ago - Neurogene Inc. Announces Pricing of $125 Million Public Offering - Business Wire
- 22 days ago - Neurogene 75M Spot Secondary; re-offered at $30.00 - TheFly
- 22 days ago - Neurogene announces common stock offering, no amount given - TheFly
- 22 days ago - Neurogene Inc. Announces Proposed Public Offering - Business Wire
- 24 days ago - Neurogene Transcript: Study result - Transcripts
- 24 days ago - Neurogene Press release: Study result - Filings